ArticleBMC medical genomics2025
Driver mutations and malignant pleural effusion in non-small cell lung cancer.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inhibitor of DNA binding 1 in lung cancer and the tumor microenvironment: a testable hypothesis for malignant pleural effusion formation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant pleural effusion (MPE) complicates approximately 50% of non-small cell lung cancer (NSCLC) cases, signaling advanced disease and poor patient outcomes. While molecular alterations such as ALK, ROS1, and T790M mutations, as well as PD-L1 expression, are critical in NSCLC progression, their relationship with MPE development remains inadequately characterized.
methodsThis retrospective cohort study examined 130 NSCLC patients (52 with MPE, 78 without MPE). Clinical characteristics and comprehensive molecular profiles were analyzed using next-generation sequencing. Statistical comparisons were performed, and a Least Absolute Shrinkage and Selection Operator (LASSO) regularized logistic regression model identified independent predictors of MPE. Model performance was evaluated using receiver operating characteristic (ROC) analysis.
resultsPD-L1 expression demonstrated a significant association with MPE development (Odds ratio = 2.78, p < 0.01), nearly tripling the likelihood of effusion. The presence of ALK, ROS1, and T790M mutations (combined OR = 2.41, p < 0.05) also showed predictive value for MPE formation. Several clinical factors independently correlated with MPE, including advanced age, heavy smoking history (> 50 pack-years), and right inferior lobe tumor location (all p < 0.05). The predictive model demonstrated robust performance with an area under the curve of 0.80.
conclusionsThese findings establish important associations between specific driver mutations and PD-L1 expression in relation to MPE development in NSCLC patients. Identifying these genetic and clinical predictors may enhance risk stratification approaches and guide personalized treatment strategies, especially for those with advanced disease. Further prospective validation studies are needed to confirm these associations and explore their therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.